1
|
Maitre P, Haris M, Portner R, Hoskin P, Hudson A, Wylie J, Logue J, Conroy R, Tran A, Serra M, Croxford W, Song Y, Oates J, Ramani V, Clarke N, Choudhury A. Outcomes in Locally Advanced Non-Metastatic Prostate Cancer Presenting with Low PSA at Diagnosis. Int J Radiat Oncol Biol Phys 2023; 117:e413-e414. [PMID: 37785368 DOI: 10.1016/j.ijrobp.2023.06.1561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Men with low serum prostate-specific antigen (PSA) and high Gleason grade group (GGG) are thought to have poor outcomes compared to high PSA secretors. However, there is limited outcome data to support this. We report clinical outcomes from a single-institutional cohort of men presenting with locally advanced prostate cancer but low serum PSA. MATERIALS/METHODS Data from electronic database of a UK tertiary cancer center was acquired for men with histological diagnosis of prostate adenocarcinoma, GGG 4 or 5, stage ≥cT3a, and PSA <10ug/L at diagnosis. Men with metastatic disease, or prior androgen deprivation therapy (ADT) were excluded. Biochemical progression was defined as per Phoenix criteria (PSA > nadir+2) for primary radiotherapy, or PSA >0.2 ug/L after primary prostatectomy (and post-operative radiotherapy, if received). Overall survival (OS, from date of diagnosis to death), metastasis-free survival (MFS, from diagnosis to first recorded metastasis or death), and biochemical progression free survival (bPFS, from diagnosis to biochemical progression or death) were estimated by Kaplan Meier method, and multivariable analysis performed using Cox proportional hazards method. RESULTS Medical records of 7,200 men presenting with non-metastatic prostate cancer from 2013 to 2021 were screened, of which 270 men satisfying the eligibility criteria were included for this study. Initial analysis of 123 men shows median PSA at presentation 7.1 ug/L (IQR 5.6-8.5), and median age 70 years (IQR 65-75). Histology was GGG 4 in 47.6% and 5 in 52.4%. Tumor stage was cT3a in 56.6%, cT3b in 36.9%, and T4 in 6.6%. Pelvic nodes were involved in 5% patients. Majority (83.7%) were treated with radical radiotherapy (external beam alone 64.2%, brachytherapy boost 19.5%), with 24 months ADT; 11.4% underwent radical prostatectomy, and 4.9% received ADT alone. Three men (2.4%) received docetaxel, and one received abiraterone. At a median follow up of 66 months (IQR 27-77), 36 (29.3%) patients had biochemical failure. Total 23 (18.6%) patients had metastases at recurrence, which were visceral in 4%, bone-only in 10%, and nodal-only in 4%. Total 38 (30.6%) patients had died, 23% with prostate cancer and 11% due to other causes. Five-year bPFS was 65.9%, MFS 69.0%, and OS was 77.4%. GGG 5 (versus 4) was associated with significantly worse 5-year bPFS (59.4% vs 73.9%, HR 1.8, 95% CI 1.0-3.2, p = 0.05) and MFS (59.2% vs 81.6%, HR 2.2, 1.2-4.2, p = 0.02). On multivariable analysis including age and PSA at diagnosis, only GGG 5 was associated with worse bPFS (HR 1.8, 1.0-3.3, p = 0.05) and MFS (HR 2.42, 1.25-4.67, p = 0.009). CONCLUSION Men with low secreting but high Gleason grade group prostate cancer are a relatively rare group with poor clinical outcomes despite being non-metastatic. Ongoing work (expected completion June 2023) will analyze remaining cases, and compare outcomes within an expanded multicentric cohort with matched controls having elevated PSA at presentation.
Collapse
Affiliation(s)
- P Maitre
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - M Haris
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - R Portner
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - P Hoskin
- Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
| | - A Hudson
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - J Wylie
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - J Logue
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - R Conroy
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - A Tran
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - M Serra
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - W Croxford
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - Y Song
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - J Oates
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - V Ramani
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - N Clarke
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - A Choudhury
- Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK, Manchester, United Kingdom
| |
Collapse
|
2
|
Spitznagel MC, Mutiso F, Oates J, Kamen D. Disparities in herpes zoster risk among patients with systemic lupus erythematosus. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00534-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
3
|
Delk VD, Mutiso F, Oates J, Kamen D. Differences in health-related quality of life between black and non-black patients with systemic lupus erythematosus. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00638-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
4
|
Patolia S, Oates J, Kamen D. Hyperlipidemia and other risk factors for cardiovascular outcomes among patients with systemic lupus erythematosus. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00632-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
5
|
Carter SP, Wilson D, Oates J. Predictors of mortality and black patient disparities in South Carolina lupus cohort. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00633-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
6
|
Meehan M, Shah A, Lobo J, Oates J, Clinton C, Annapureddy N, Xie F, Zhuo J, Danila MI, England BR, Curtis JR. Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis. Arthritis Res Ther 2022; 24:2. [PMID: 34980225 PMCID: PMC8722182 DOI: 10.1186/s13075-021-02655-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Accepted: 10/12/2021] [Indexed: 11/23/2022] Open
Abstract
Background/purpose Interstitial lung disease (ILD) is an important problem for patients with rheumatoid arthritis (RA). However, current approaches to ILD case finding in real-world data have been evaluated only in limited settings and identify only prevalent ILD and not new-onset disease. Our objective was to develop, refine, and validate a claims-based algorithm to identify both prevalent and incident ILD in RA patients compared to the gold standard of medical record review. Methods We used administrative claims data 2006–2015 from Medicare to derive a cohort of RA patients. We then identified suspected ILD using variations of ILD algorithms to classify both prevalent and incident ILD based on features of the data that included hospitalization vs. outpatient setting, physician specialty, pulmonary-related diagnosis codes, and exclusions for potentially mimicking pulmonary conditions. Positive predictive values (PPV) of several ILD algorithm variants for both prevalent and incident ILD were evaluated. Results We identified 234 linkable RA patients with sufficient data to evaluate for ILD. Overall, 108 (46.2%) of suspected cases were confirmed as ILD. Most cases (64%) were diagnosed in the outpatient setting. The best performing algorithm for prevalent ILD had a PPV of 77% (95% CI 67–84%) and for incident ILD was 96% (95% CI 85–100%). Conclusion Case finding in administrative data for both prevalent and incident interstitial lung disease in RA patients is feasible and has reasonable accuracy to support population-based research and real-world evidence generation. Supplementary Information The online version contains supplementary material available at 10.1186/s13075-021-02655-z.
Collapse
Affiliation(s)
- M Meehan
- University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, AL, Birmingham, USA
| | - A Shah
- Duke University, Durham, NC, USA
| | - J Lobo
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - J Oates
- Medical University of South Carolina, Charleston, SC, USA
| | - C Clinton
- University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, AL, Birmingham, USA
| | - N Annapureddy
- Vanderbilt University Medical Center, Nashville, TN, USA
| | - F Xie
- University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, AL, Birmingham, USA
| | - J Zhuo
- Bristol Myers Squibb, New York, USA
| | - M I Danila
- University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, AL, Birmingham, USA
| | - B R England
- University of Nebraska Medical Center, Omaha, NE, USA.,Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, USA
| | - J R Curtis
- University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, AL, Birmingham, USA.
| |
Collapse
|
7
|
Fankhauser C, Issa A, Lee E, Oing C, Oliveira P, Parnham A, Oates J, Sangar V, Gulamhusein A, Clarke N. Radical hemiscrotectomy and en-bloc orchidectomy: Surgical technique, perioperative and oncologic outcomes of a supra-regional UK referral centre. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01615-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Baik J, Lee T, Oates J, Aziz O, Wilson M, Shenjere P, Shanks J, Oliveira P, Wylie J, Leahy M, Sangar V, Clarke N. Surgical outcomes of adult patients with abdominopelvic sarcomas. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32944-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Abstract
Background Staff well-being is vital to the functioning of the UK National Health Service (NHS). Mental health nurses (MHNs) with personal experience of mental illness can offer a professionally and personally informed insight into the occupational health (OH) service offered by their employer. Aims To investigate MHNs' views of OH provision in the NHS, based on their personal experience. Methods A qualitative interview study using a purposive sample of MHNs with personal experience of mental illness. Results Twenty-seven MHNs met the inclusion criteria. Thematic analysis identified three themes: comparisons of 'relative expertise' between the mental health nurse and the OH clinician; concerns about 'being treated' by a service at their work; and 'returning to work'. Conclusions OH provision in mental health settings must take account of the expertise of its staff. Further research, looking at NHS OH provision from the provider perspective is warranted.
Collapse
Affiliation(s)
- J Oates
- Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, London, UK
| | - J Jones
- Centre for Research in Primary and Community Care (CRIPACC), School of Health and Social Work, University of Hertfordshire, Hat?eld, UK
| | - N Drey
- School of Health Sciences, City, University of London, Northampton Square, London, UK
| |
Collapse
|
10
|
Fontana E, Ragulan C, Cunningham D, Hulkki-Wilson S, Sclafani F, Nyamundanda G, Eason K, Begum R, Chong I, Peckitt C, Bali M, Oates J, Watkins D, Rao S, Hubank M, Wotherspoon A, Valeri N, Chau I, Starling N, Sadanandam A. Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Sclafani F, Brown G, Cunningham D, Wotherspoon A, Sena Teixeira Mendes L, Evans J, Peckitt C, Begum R, Tait D, Capdevila J, Glimelius B, Roselló S, Thomas J, Oates J, Chau I. Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Oates J, Drey N, Jones J. 'Your experiences were your tools'. How personal experience of mental health problems informs mental health nursing practice. J Psychiatr Ment Health Nurs 2017; 24:471-479. [PMID: 28192640 DOI: 10.1111/jpm.12376] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/09/2017] [Indexed: 01/14/2023]
Abstract
UNLABELLED WHAT IS KNOWN ON THE SUBJECT?: 'Expertise by experience' has become an increasingly valued element of service design and delivery by mental health service providers. The extent and influence of mental health professionals' personal experience of mental ill health on clinical practice has seldom been interrogated in depth. WHAT THIS PAPER ADDS TO EXISTING KNOWLEDGE?: We investigate how mental health nurses' own personal experience of mental ill health informs their mental health nursing practice with particular reference to direct work with service users. Participants said that personal experience could impact on work in three positive ways: to develop their relationship with service users, to enhance their understanding of service users and as a motivation for potential mental health nurses to join the profession. This study moves the discussion of the state of mental health nurses' mental health further towards the recovery and well-being focus of contemporary mental health care, where 'expertise by experience' is highly valued. WHAT ARE THE IMPLICATIONS FOR PRACTICE?: We must address the taboo of disclosure within clinical nursing practice and debate the extent to which personal and professional boundaries are negotiated during clinical encounters. ABSTRACT Introduction 'Expertise by experience' is a highly valued element of service delivery in recovery-oriented mental health care, but is unacknowledged within the mental health nursing literature. Aim To explore the extent and influence of mental health professionals' personal experience of mental ill health on clinical practice. Method Twenty-seven mental health nurses with their own personal experience of mental ill health were interviewed about how their personal experience informed their mental health nursing practice, as part of a sequential mixed methods study. Results The influence of personal experience in nursing work was threefold: first, through overt disclosure; second, through the 'use of the self as a tool'; and third, through the formation of professional nursing identity. Discussion Mental health nurses' experience of mental illness was contextualized by other life experiences and by particular therapeutic relationships and clinical settings. In previous empirical studies, nurses have cited personal experience of mental illness as a motivator and an aspect of their identity. In this study, there was also an association between personal experience and enhanced nursing expertise. Implications for practice If drawing on personal experience is commonplace, then we must address the taboo of disclosure and debate the extent to which personal and professional boundaries are negotiated during clinical encounters.
Collapse
Affiliation(s)
- J Oates
- Florence Nightingale Faculty of Nursing and Midwifery, King's College London, London, UK
| | - N Drey
- School of Health Sciences, City University London, London, UK
| | - J Jones
- Patient Experience and Public Involvement, Centre for Research in Primary and Community Care (CRIPACC), School of Health and Social Work, University of Hertfordshire, Hatfield, UK
| |
Collapse
|
13
|
Affiliation(s)
- J Oates
- Faculty of Nursing & Midwifery, King's College London, London, UK
| |
Collapse
|
14
|
Veitch P, Oates J. Strange bedfellows? Nurses as Responsible Clinicians under the Mental Health Act (England & Wales). J Psychiatr Ment Health Nurs 2017; 24:243-251. [PMID: 27973700 DOI: 10.1111/jpm.12366] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/02/2016] [Indexed: 11/28/2022]
Affiliation(s)
- P Veitch
- Northumberland Tyne and Wear NHS Foundation Trust, St Nicholas Hospital, Newcastle upon Tyne, UK
| | - J Oates
- Florence Nightingale Faculty of Nursing & Midwifery, King's College London, London, UK
| |
Collapse
|
15
|
Jackson K, Frame J, Oates J, Wilson S. An effective view. Health Informatics J 2016. [DOI: 10.1177/146045829900500205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The Victoria Infirmary National Health Service (NHS) Trust, Glasgow, UK has recently completed the pilot phase of implementing an internal Intranet system. The project was initially funded by the NHS Management Executive with the purpose of establishing an internal web to provide non-patient specific clinical and non-clinical information throughout the Trust. The pilot phase has been a great success, with the Intranet content currently consisting of departmental information, protocols, clinical guidelines and notices of meetings. The Intranet is now beginning to take on the function of a hospital handbook.
Collapse
Affiliation(s)
- K. Jackson
- Victoria Infirmary NHS Trust, Clinical Audit Department, Glasgow, G42 9TY, UK,
| | - J. Frame
- Victoria Infirmary NHS Trust, Clinical Audit Department, Glasgow, G42 9TY, UK
| | - J. Oates
- Victoria Infirmary NHS Trust, Clinical Audit Department, Glasgow, G42 9TY, UK
| | - S. Wilson
- Victoria Infirmary NHS Trust, Clinical Audit Department, Glasgow, G42 9TY, UK
| |
Collapse
|
16
|
Walshaw R, Taylor J, Warburton H, Oates J, Husain J, Keegan, Burke D, German A, Elliott T. Orchestrating timely check cystoscopy after radical radiotherapy to the bladder. Clin Oncol (R Coll Radiol) 2016. [DOI: 10.1016/j.clon.2016.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol 2016; 27:1557-65. [PMID: 27217542 DOI: 10.1093/annonc/mdw215] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 05/13/2016] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). DESIGN We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Prognostic factors were also analysed. RESULTS A total of 269 patients were included. Of these, 91.1% completed NACT, 88.1% completed CRT and 240 (89.2%) underwent curative surgery (R0/R1). After a median follow-up of 71.9 months, 5-year progression-free survival (PFS) and OS were 66.4% and 73.3%, respectively. In the group of R0/R1 resection patients, 5-year relapse-free survival (RFS) and OS were 71.6% and 77.2%, respectively, with local recurrence occurring in 5.5% and distant metastases in 20.6% of cases. Significant prognostic factors after multivariate analyses included age, tumour grade and MRI extramural venous invasion (mrEMVI) at baseline, MRI tumour regression grade (mrTRG) after CRT, ypT stage after surgery and adherence to study treatment. mrTRG after NACT was associated with PFS (P = 0.002) and OS (P = 0.018) and appeared to stratify patients based on the incremental benefit from sequential CRT. Among the outcome measures considered, in the subgroup of R0/R1 resection patients, ypT and ypStage had the highest predictive accuracy for RFS (concordance index: 0.6238 and 0.6252, respectively) and OS (concordance index: 0.6094 and 0.6132, respectively). CONCLUSIONS Administering NACT before CRT could be a potential strategy for high-risk LARC. In this setting, mrTRG after CRT is an independent prognostic factor, while mrTRG after NACT should be tested as a parameter for treatment selection in trials of NACT ± CRT. ypT stage may be a valuable surrogate end point for future phase II trials investigating intensified neoadjuvant treatments in similar patient populations.
Collapse
Affiliation(s)
| | | | | | | | | | - C Peckitt
- Department of Clinical Research & Development, The Royal Marsden NHS Foundation Trust, London and Surrey, UK
| | | | | | | | - J Tabernero
- Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - B Glimelius
- Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala, Uppsala, Sweden
| | - A Cervantes
- Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
| | | | | | | | | |
Collapse
|
18
|
Grenader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D, Bridgewater J. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol 2016; 27:687-92. [PMID: 26787231 DOI: 10.1093/annonc/mdw012] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2015] [Accepted: 12/30/2015] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The REAL-2 trial demonstrated that capecitabine and oxaliplatin were effective alternatives to fluorouracil and cisplatin, respectively, when used in triplet chemotherapy regimens for previously untreated oesophago-gastric cancer. The aim of the current analysis was to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in the REAL-2 cohort. MATERIAL AND METHODS A post hoc exploratory analysis was carried out on REAL-2 patients with the available absolute neutrophil count and absolute lymphocyte count. A high NLR was defined using a cut-off value of >3.0. The NLR was then correlated with clinical outcomes including overall survival (OS), progression-free survival (PFS) and objective response rate. Survival curves were generated using the Kaplan-Meier method and comparison between groups was carried out using Cox regression. RESULTS Data were available in 908 of the 1002 REAL-2 participants. Of these, 516 (56.8%) were deemed to have a high NLR. In univariate analysis, high NLR was associated with a hazard ratio (HR) for OS of 1.73 (1.50-2.00), P < 0.001, compared with low NLR, equating to median OS values of 9.1 [95% confidence interval (CI) 8.0-9.6] and 12.7 months (95% CI 10.8-14.4), respectively. The NLR remained highly significant for OS (P < 0.001) in a multivariate model including performance status, age, disease extent, presence of liver metastases and presence of peritoneal metastases. For PFS, high NLR was associated with an HR of 1.63 (1.41-1.87), P < 0.001, compared with low NLR in univariate analysis. No significant interaction was found between NLR status and treatment arm, 13% of all patients with low NLR achieving survival beyond 24 months compared with only 6% of patients with high NLR (P < 0.001). CONCLUSION Our results confirm that high NLR status had a significant negative prognostic effect in the REAL-2 trial population. Based on the multivariate analysis, this effect was independent of other known prognostic factors.
Collapse
Affiliation(s)
- T Grenader
- Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel
| | - T Waddell
- Section of GI and Lymphoma Units, Department of Medicine, The Royal Marsden Hospital, London
| | - C Peckitt
- Clinical Research and Development, The Royal Marsden NHS Foundation Trust, London
| | - J Oates
- Section of GI and Lymphoma Units, Department of Medicine, The Royal Marsden Hospital, London
| | - N Starling
- Section of GI and Lymphoma Units, Department of Medicine, The Royal Marsden Hospital, London
| | - D Cunningham
- Section of GI and Lymphoma Units, Department of Medicine, The Royal Marsden Hospital, London
| | - J Bridgewater
- Department of Oncology, UCL Cancer Institute, London, UK
| |
Collapse
|
19
|
Keijser W, de Manuel-Keenoy E, d'Angelantonio M, Stafylas P, Hobson P, Apuzzo G, Hurtado M, Oates J, Bousquet J, Senn A. DG Connect Funded Projects on Information and Communication Technologies (ICT) for Old Age People: Beyond Silos, CareWell and SmartCare. J Nutr Health Aging 2016; 20:1024-1033. [PMID: 27925142 DOI: 10.1007/s12603-016-0804-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Information and communication technologies (ICT) are promising for the long-term care of older and frequently frail people. These innovations can improve health outcomes, quality of life and efficiency of care processes, while supporting independent living. However, they may be disruptive innovations. As all European member states are facing an increasing complexity of health and social care, good practices in ICT should be identified and evaluated. Three projects funded by DG CNECT are related to Active and Healthy Ageing (AHA) and frailty: (i) BeyondSilos, dealing with independent living and integrated services, (ii) CareWell, providing integrated care coordination, patient empowerment and home support and (iii) SmartCare, proposing a common set of standard functional specifications for an ICT platform enabling the delivery of integrated care to older patients. The three projects described in this paper provide a unique pan-European research field to further study implementation efforts and outcomes of new technologies. Below, based on a description of the projects, the authors display four domains that are in their views fundamental for in-depth exploration of heterogeneity in the European context: 1. Definition of easily transferable, high level pathways with solid evidence-base; 2. Change management in implementing ICT enabled integrated care; 3. Evaluation and data collection methodologies based on existing experience with MAST and MEDAL methodologies; and 4. Construction of new models for delivery of health and social care. Understanding complementarity, synergies and differences between the three unique projects can help to identify a more effective roll out of best practices within a varying European context.
Collapse
Affiliation(s)
- W Keijser
- Jean Bousquet. CHRU Montpellier, 24295- Montpellier Cedex 5, France,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Grenader T, Waddell T, Peckitt C, Bridgewater J, Oates J, Cunningham D. 2310 Prognostic value of neutrophil to lymphocyte ratio (NLR) in advanced oesophagogastric cancer: Exploratory analysis of data from the REAL-2 trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31226-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Ann Oncol 2015; 26:1936-1941. [PMID: 26162609 PMCID: PMC4551162 DOI: 10.1093/annonc/mdv285] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Revised: 05/29/2015] [Accepted: 06/26/2015] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. PATIENTS AND METHODS We analysed rs61764370 in EXPERT-C, a randomised phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX plus or minus cetuximab in locally advanced rectal cancer. DNA was isolated from formalin-fixed paraffin-embedded tumour tissue and genotyped using a PCR-based commercially available assay. Kaplan-Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment arms. RESULTS A total of 155/164 (94.5%) patients were successfully analysed, of whom 123 (79.4%) and 32 (20.6%) had the LCS-6 TT and LCS-6 TG genotype, respectively. Carriers of the G allele were found to have a statistically significantly higher rate of complete response (CR) after neoadjuvant therapy (28.1% versus 10.6%; P = 0.020) and a trend for better 5-year progression-free survival (PFS) [77.4% versus 64.5%: hazard ratio (HR) 0.56; P = 0.152] and overall survival (OS) rates (80.3% versus 71.9%: HR 0.59; P = 0.234). Both CR and survival outcomes were independent of the use of cetuximab. The negative prognostic effect associated with KRAS mutation appeared to be stronger in patients with the LCS-6 TT genotype (HR PFS 1.70, P = 0.078; HR OS 1.79, P = 0.082) compared with those with the LCS-6 TG genotype (HR PFS 1.33, P = 0.713; HR OS 1.01, P = 0.995). CONCLUSION This analysis suggests that rs61764370 may be a biomarker of response to neoadjuvant treatment and an indicator of favourable outcome in locally advanced rectal cancer possibly by mitigating the poor prognosis of KRAS mutation. In this setting, however, this polymorphism does not appear to predict cetuximab benefit.
Collapse
Affiliation(s)
- F Sclafani
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - I Chau
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - D Cunningham
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - C Peckitt
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - A Lampis
- Division of Molecular Pathology, The Institute of Cancer Research, London and Sutton
| | - J C Hahne
- Division of Molecular Pathology, The Institute of Cancer Research, London and Sutton
| | - C Braconi
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey; Division of Cancer Therapeutics, The Institute of Cancer Research, London and Sutton, UK
| | - J Tabernero
- Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - B Glimelius
- Department of Immunology, Genetics and Pathology, University of Uppsala, Uppsala, Sweden
| | - A Cervantes
- Department of Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
| | - R Begum
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - D Gonzalez De Castro
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - S Hulkki Wilson
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - Z Eltahir
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - A Wotherspoon
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - D Tait
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - G Brown
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - J Oates
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - N Valeri
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey; Division of Molecular Pathology, The Institute of Cancer Research, London and Sutton.
| |
Collapse
|
22
|
Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Oates J, Chau I. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. Eur J Cancer 2014; 50:1430-6. [PMID: 24582914 DOI: 10.1016/j.ejca.2014.02.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Revised: 01/28/2014] [Accepted: 02/02/2014] [Indexed: 01/17/2023]
Abstract
BACKGROUND RAS mutations predict resistance to anti-epidermal growthfactor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. We analysed RAS mutations in 30 non-metastatic rectal cancer patients treated with or without cetuximab within the 31 EXPERT-C trial. METHODS Ninety of 149 patients with tumours available for analysis were KRAS/BRAF wild-type, and randomly assigned to capecitabine plus oxaliplatin (CAPOX) followed by chemoradiotherapy, surgery and adjuvant CAPOX or the same regimen plus cetuximab (CAPOX-C). Of these, four had a mutation of NRAS exon 3, and 84 were retrospectively analysed for additional KRAS (exon 4) and NRAS (exons 2/4) mutations by using bi-directional Sanger sequencing. The effect of cetuximab on study end-points in the RAS wild-type population was analysed. RESULTS Eleven (13%) of 84 patients initially classified as KRAS/BRAF wild-type were found to have a mutation in KRAS exon 4 (11%) or NRAS exons 2/4 (2%). Overall, 78/149 (52%) assessable patients were RAS wild-type (CAPOX, n=40; CAPOX-C, n=38). In this population, after a median follow-up of 63.8months, in line with the initial analysis, the addition of cetuximab was associated with numerically higher, but not statistically significant, rates of complete response (15.8% versus 7.5%, p=0.31), 5-year progression-free survival (75.5% versus 67.5%, hazard ratio (HR) 0.61, p=0.25) and 5-year overall survival (83.8% versus 70%, HR 0.54, p=0.20). CONCLUSIONS RAS mutations beyond KRAS exon 2 and 3 were identified in 17% of locally advanced rectal cancer patients. Given the small sample size, no definitive conclusions on the effect of additional RAS mutations on cetuximab treatment in this setting can be drawn and further investigation of RAS in larger studies is warranted.
Collapse
Affiliation(s)
- F Sclafani
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - D Gonzalez
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - D Cunningham
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
| | - S Hulkki Wilson
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - C Peckitt
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - J Giralt
- Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - B Glimelius
- Akademiska Sjukhuset Uppsala, Uppsala, Sweden
| | - S Roselló Keränen
- Institute of Health Research Hospital Clinic of Valencia, University of Valencia, Valencia, Spain
| | - A Wotherspoon
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - G Brown
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - D Tait
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - J Oates
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - I Chau
- The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| |
Collapse
|
23
|
Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. Eur J Cancer 2014; 50:1422-9. [PMID: 24613126 DOI: 10.1016/j.ejca.2014.02.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 01/28/2014] [Accepted: 02/02/2014] [Indexed: 12/29/2022]
Abstract
BACKGROUND Preclinical data support the combined inhibition of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways in the treatment of pancreatic cancer. Following a dose finding phase I study the efficacy and toxicity of a four-drug regimen utilising the cytotoxic doublet of gemcitabine and capecitabine (GemCap), with the biological doublet of erlotinib and bevacizumab were further assessed in patients with advanced pancreatic cancer. PATIENTS AND METHODS In a phase II expansion cohort, patients with chemonaive locally advanced or metastatic pancreatic cancer received gemcitabine (1000mg/m(2) D1, 8, 15), capecitabine (1400mg/m(2) D1-21), erlotinib (100mg daily) and bevacizumab (5mg/kg D1, 15) every 28days. The primary endpoint was radiological response rate by response evaluation criteria in solid tumours (RECIST). Computed tomography (CT) assessment was performed every 8weeks. Consolidation radiotherapy was considered in locally advanced patients following six cycles of treatment. RESULTS In total 44 patients (phases I & II) were recruited. The median cycles delivered were 6 (range 1-16). Confirmed radiological responses were seen in 23% (95% confidence interval (CI): 11-38%) of patients. The median progression-free and overall survival for the entire cohort was 8.4 and 12.6months, respectively. In patients with metastatic disease the median overall survival was 10.1months. Common grade 3/4 toxicities were; neutropenia 52%, lethargy 32%, diarrhoea 18% and hand-foot syndrome 18%. CONCLUSION The combination of gemcitabine, capecitabine, erlotinib and bevacizumab was feasible with a manageable toxicity profile and demonstrated encouraging efficacy data in a good performance status population.
Collapse
Affiliation(s)
- D J Watkins
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| | - N Starling
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| | - D Cunningham
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom.
| | - J Thomas
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| | - J Webb
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| | - G Brown
- Department of Diagnostic Imaging, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| | - Y Barbachano
- Computing and Statistics, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| | - J Oates
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| | - I Chau
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, United Kingdom
| |
Collapse
|
24
|
Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabernero J, Glimelius B, Cervantes A, Eltahir Z, Oates J, Chau I. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Ann Oncol 2013; 24:3123-8. [PMID: 24146218 DOI: 10.1093/annonc/mdt408] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX and CRT±cetuximab in the EXPERT-C trial. PATIENTS AND METHODS Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric cancer. Tumours with equivocal IHC result (2+) were tested for HER2 amplification by D-ISH. Tumours with IHC 3+ or D-ISH ratio ≥2.0 were classified as HER2+. The impact of HER2 on primary and secondary end points of the study was analysed. RESULTS Of 164 eligible study patients, 104 (63%) biopsy and 114 (69%) surgical specimens were available for analysis. Only 3 of 104 (2.9%) and 3 of 114 (2.6%) were HER2+, respectively. In 77 patients with paired specimens, concordance for HER2 status was found in 74 (96%). Overall, 141 patients were assessable for HER2 and 6 out of 141 (4.3%) had HER2 overexpression and/or amplification. The median follow-up was 58.6 months. HER2 was not associated with a difference in the outcome for any of the study end points, including in the subset of 90 KRAS/BRAF wild-type patients treated±cetuximab. CONCLUSIONS Based on the low prevalence of expression as recorded in the EXPERT-C trial, HER2 does not appear to represent a useful therapeutic target in high-risk rectal cancer. However, the role of HER2 as a potential predictive biomarker of resistance to anti-EGFR-based treatments and a therapeutic target in anti-EGFR refractory metastatic colorectal cancer (CRC) warrants further investigation. TRIAL REGISTRATION ISRCTN Register: 99828560.
Collapse
Affiliation(s)
- F Sclafani
- The Royal Marsden NHS Foundation Trust, London & Surrey, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382:769-79. [PMID: 23726390 PMCID: PMC3778977 DOI: 10.1016/s0140-6736(13)60900-9] [Citation(s) in RCA: 1106] [Impact Index Per Article: 100.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors (coxibs) and traditional non-steroidal anti-inflammatory drugs (tNSAIDs), are not well characterised, particularly in patients at increased risk of vascular disease. We aimed to provide such information through meta-analyses of randomised trials. METHODS We undertook meta-analyses of 280 trials of NSAIDs versus placebo (124,513 participants, 68,342 person-years) and 474 trials of one NSAID versus another NSAID (229,296 participants, 165,456 person-years). The main outcomes were major vascular events (non-fatal myocardial infarction, non-fatal stroke, or vascular death); major coronary events (non-fatal myocardial infarction or coronary death); stroke; mortality; heart failure; and upper gastrointestinal complications (perforation, obstruction, or bleed). FINDINGS Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1·37, 95% CI 1·14-1·66; p=0·0009) or diclofenac (1·41, 1·12-1·78; p=0·0036), chiefly due to an increase in major coronary events (coxibs 1·76, 1·31-2·37; p=0·0001; diclofenac 1·70, 1·19-2·41; p=0·0032). Ibuprofen also significantly increased major coronary events (2·22, 1·10-4·48; p=0·0253), but not major vascular events (1·44, 0·89-2·33). Compared with placebo, of 1000 patients allocated to a coxib or diclofenac for a year, three more had major vascular events, one of which was fatal. Naproxen did not significantly increase major vascular events (0·93, 0·69-1·27). Vascular death was increased significantly by coxibs (1·58, 99% CI 1·00-2·49; p=0·0103) and diclofenac (1·65, 0·95-2·85, p=0·0187), non-significantly by ibuprofen (1·90, 0·56-6·41; p=0·17), but not by naproxen (1·08, 0·48-2·47, p=0·80). The proportional effects on major vascular events were independent of baseline characteristics, including vascular risk. Heart failure risk was roughly doubled by all NSAIDs. All NSAID regimens increased upper gastrointestinal complications (coxibs 1·81, 1·17-2·81, p=0·0070; diclofenac 1·89, 1·16-3·09, p=0·0106; ibuprofen 3·97, 2·22-7·10, p<0·0001; and naproxen 4·22, 2·71-6·56, p<0·0001). INTERPRETATION The vascular risks of high-dose diclofenac, and possibly ibuprofen, are comparable to coxibs, whereas high-dose naproxen is associated with less vascular risk than other NSAIDs. Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making. FUNDING UK Medical Research Council and British Heart Foundation.
Collapse
|
26
|
Oates J, Manica A, Bshary R, Grutter AS. Relationship between roving behaviour and the diet and client composition of the cleaner fish Labroides bicolor. J Fish Biol 2012; 81:210-219. [PMID: 22747814 DOI: 10.1111/j.1095-8649.2012.03330.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Diet analyses and observations of cleaning behaviour of two cleaner fishes revealed that Labroides bicolor fed more on client mucus, but Labroides dimidiatus fed more on ectoparasites, and that L. bicolor interacted with fewer species (36 species) compared with L. dimidiatus (44 species). The client species which contributed most to the dissimilarity between cleaner species were the dusky farmerfish Stegastes nigricans and bicolor chromis Chromis margaritifer damselfishes, which L. dimidiatus interacted with more often than L. bicolor, and the striated Ctenochaetus striatus and brown Acanthurus nigrofuscus surgeonfishes, which L. bicolor interacted with more; L. bicolor interacted with all parrotfishes (Scaridae) more. These results confirm the importance of repeated interactions and partner choice in determining the nature of interactions in mutualisms.
Collapse
Affiliation(s)
- J Oates
- Evolutionary Ecology Group, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, U.K
| | | | | | | |
Collapse
|
27
|
Casikar I, Lu C, Oates J, Bignardi T, Alhamdan D, Condous G. The use of power Doppler colour scoring to predict successful expectant management in women with an incomplete miscarriage. Hum Reprod 2012; 27:669-75. [DOI: 10.1093/humrep/der433] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Starling N, Hawkes EA, Chau I, Watkins D, Thomas J, Webb J, Brown G, Thomas K, Barbachano Y, Oates J, Cunningham D. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Ann Oncol 2011; 23:942-7. [PMID: 21750117 DOI: 10.1093/annonc/mdr317] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Targeting platelet-derived growth factor receptor-β (PDGFR-β) is a potential strategy to reduce tumour-related interstitial fluid pressure, enhance cytotoxic drug uptake and reduce chemoresistance. This study aimed to define safe doses of gemcitabine plus oxaliplatin when combined with imatinib (potent PDGFR-β inhibitor) in patients with advanced gemcitabine-refractory pancreatic cancer (PC). PATIENTS AND METHODS Using a 3 + 3 dose escalation design, patients of performance status zero or one were entered into five sequential dose levels (DLs) of gemcitabine [day 1, from 400 (DL1) to 1000 mg/m(2) (DL4)] and oxaliplatin [day 2, 85 (DL1-4) and 100 mg/m(2) (DL5)] two weekly. Imatinib 400 mg od was given for 7 days (day minus 2-5) each cycle. RESULTS Twenty-seven patients received 168 cycles in total. Median age was 61 years (44-74 years). Dose-limiting toxicities occurred in two of two patients at DL5 (G4 thrombocytopenia, G3 lethargy), defined as the maximum tolerated dose and one of six patients at DL4 (G3 lethargy). DL4 was expanded. There were 2 of 27 partial responses and 14 of 27 stable disease [disease control 52%, 95% confidence interval (CI) 32% to 71%]. Median progression-free survival and overall survival were 4.6 (95% CI 2.1-7.0) and 5.6 months (95% CI 2.5-8.7), respectively. CONCLUSION In gemcitabine-refractory PC, gemcitabine (1000 mg/m(2)) and oxaliplatin (85 mg/m(2)) can be safely combined with imatinib given on a 7 days on and 7 days off intermittent schedule.
Collapse
Affiliation(s)
- N Starling
- Department of Medicine,Royal Marsden Hospital, NHS Foundation Trust, Surrey and London, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Buckley K, O'Halloran P, Oates J. Voice and vocal health in elite sports coaching: considerations for elite football coaching staff. Br J Sports Med 2011. [DOI: 10.1136/bjsm.2011.084038.78] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Murray PG, Oates J, Reynolds GM, Crocker J, Young LS. Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus infection. Mol Pathol 2010; 48:M105-8. [PMID: 16695980 PMCID: PMC407934 DOI: 10.1136/mp.48.2.m105] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Aim-To examine the expression of CD40 and B7 (CD80) antigens and the CD40 ligand in Hodgkin's disease.Methods-Antigen and ligand expression was studied in 17 cases of Hodgkin's disease using immunohistochemistry. The study included 11 cases of Hodgkin's disease in which latent Epstein-Barr virus (EBV) infection could be demonstrated within tumour cells by in situ hybridisation for the EBV encoded early RNAs (EBERs).Results-In all cases, irrespective of EBV status, Reed-Sternberg cells and their variants (HRS cells) showed strong expression of both B7 and CD40 antigens. CD40 ligand expression was not shown in HRS cells but was confined to a subset of small lymphocytes some of which were seen to be in intimate contact with HRS cells.Paraffin wax sections from a further 60 cases of Hodgkin's disease were examined for CD40 and EBER expression alone. The CD40 antigen was identified in HRS cells in all of these cases irrespective of EBER expression.Conclusions-As CD40 and B7 expression are features of professional antigen presenting cells, these results provide further evidence that HRS cells may have antigen presenting properties and that this may contribute to the characteristic recruitment and activation of non-malignant lymphocytes which is a feature of Hodgkin's disease. The ability of HRS cells to activate T(h) cells may in turn contribute to their own survival through the induction of the gp39/CD40 pathway.
Collapse
Affiliation(s)
- P G Murray
- Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TJ
| | | | | | | | | |
Collapse
|
31
|
Afford SC, Kakoullis T, Oates J, Crocker J, Strain AJ. Effects of hepatocyte growth factor on differentiation and cMET receptor expression in the promyelocytic HL60 cell line. Mol Pathol 2010; 48:M23-7. [PMID: 16695971 PMCID: PMC407915 DOI: 10.1136/mp.48.1.m23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Aim-To determine the effects of hepatocyte growth factor (HGF) on myeloid cell differentiation and cMET expression using the promyelocytic HL60 cell line.Methods-HL60 cells cultured with purified recombinant HGF, dimethyl sulphoxide (DMSO), or 12-O tetradecanoylphorbol-13-acetate (TPA) were immunostained for the differentiation markers, human neutrophil elastase (HNE), cathepsin B, MAC387, or the receptor for hepatocyte growth factor (cMET).Results-HGF treated cells were positive on staining for cathepsin B and MAC387, but were negative for HNE, indicating monocytic differentiation. HGF treated cells had the morphology of monocytes but continued to divide at the same rate as control cells and remained non-adherent. DMSO treated cells were positive for HNE and cell numbers were reduced, confirming myeloid differentiation. TPA treated cells were positive for cathepsin B and MAC387, cell numbers were reduced, and the cells became adherent, confirming terminal monocytic differentiation. Untreated HL60 cells were weakly positive for cMET at the start of the culture period and expression increased after 72 hours. Cells treated with HGF, DMSO, or TPA were also positive for cMET.Conclusions-These data suggest that HGF induced partial monocytic differentiation in HL60 cells. In addition, expression of cMET by HL60 cells occurs at an early stage in myelomonocytic cells and is maintained after differentiation along either the myeloid or monocytic pathways.
Collapse
Affiliation(s)
- S C Afford
- The Liver Research Laboratories, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH
| | | | | | | | | |
Collapse
|
32
|
Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, Valladares-Ayerbes M, Wilke H, Archer C, Kurek R, Beadman C, Oates J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21:2213-2219. [PMID: 20497967 DOI: 10.1093/annonc/mdq247] [Citation(s) in RCA: 94] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Clinical data showed promising antitumour activity with feasible tolerability for matuzumab plus epirubicin, cisplatin and capecitabine (ECX) chemotherapy in untreated advanced oesophago-gastric (OG) cancer. The aim was to evaluate the efficacy of matuzumab plus ECX versus ECX alone. PATIENTS AND METHODS In this multicentre, randomised open-label phase II study, 72 patients with metastatic OG cancer were randomly assigned to either 800 mg matuzumab weekly plus epirubicin 50 mg/m², cisplatin 60 mg/m² on day 1 and capecitabine 1250 mg/m² daily in a 21-day cycle (ECX) or the same ECX regimen alone. The primary end point was objective response. Secondary end points included progression-free survival (PFS), overall survival (OS), quality of life, safety and tolerability. RESULTS Following random assignment, 35 patients (median age 59 years) received ECX/matuzumab and 36 patients (median age 64 years) ECX. The addition of matuzumab to ECX did not improve objective response: 31% for ECX/matuzumab [95% confidence interval (CI) 17-49] compared with 58% for the ECX arm (95% CI 41-74) P = 0.994 (one sided). There was no significant difference in median PFS: 4.8 months (95% CI 2.9-8.1) for ECX/matuzumab versus 7.1 months (95% CI 4.4-8.5) for ECX, or in median OS: 9.4 months (95% CI 7.5-16.2), compared with 12.2 months (95% CI 9.8-13.8 months). Grade 3/4 treatment-related toxicity was observed in 27 and 25 patients in the ECX/matuzumab and ECX groups, respectively. CONCLUSION Matuzumab 800 mg weekly combined with ECX chemotherapy does not increase response or survival for patients with advanced OG cancer. Therefore, ECX/matuzumab should not be examined further in phase III trials.
Collapse
Affiliation(s)
- S Rao
- Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK
| | - N Starling
- Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK
| | - D Cunningham
- Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK.
| | - K Sumpter
- Oncology Department, Newcastle General Hospital, Newcastle, UK
| | - D Gilligan
- Oncology Department, Addenbrooke's NHS Trust, Cambridge, UK
| | - T Ruhstaller
- Department of Haematology and Oncology, St Gallen, Switzerland
| | - M Valladares-Ayerbes
- Department of Medical Oncology, Complejo Hospitalario Juan Canalejo, A Coruña, Spain
| | - H Wilke
- Oncology Department, Kliniken Essen-Mitte, Essen, Germany
| | - C Archer
- Oncology Department, St Mary's Hospital, Portsmouth, UK
| | - R Kurek
- Gastrointestinal Oncology, Merck Serono, Darmstadt, Germany
| | - C Beadman
- Gastrointestinal Oncology, Merck Serono, Darmstadt, Germany
| | - J Oates
- Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK
| |
Collapse
|
33
|
Dave Y, Milne G, Fahrenholz J, Oates J. 15-Lte4 Levels In AERD. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol 2009; 122:193-9. [PMID: 19887775 DOI: 10.1159/000253026] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2008] [Accepted: 07/01/2009] [Indexed: 11/19/2022]
Abstract
BACKGROUND The Follicular Lymphoma International Prognostic Index (FLIPI) allows physicians to stratify patients into groups with distinct prognoses, however its ability to predict the treatment efficacy has not been fully investigated. The aim of this study was to validate on this respect the FLIPI system in an independent cohort and compare it with the International Prognostic Index (IPI) used for aggressive lymphomas. METHODS Records from patients referred to our unit with a diagnosis of follicular lymphoma (FL) were retrospectively reviewed. Data required for FLIPI and IPI scores were collected along with data regarding first-line chemotherapy and time to treatment failure (TTF) and overall survival (OS). RESULTS Of 162 patients screened, 130 were assessable for both (FLIPI and IPI) scores. OS for low-risk (LR) patients identified either with IPI or FLIPI was significantly longer compared to intermediate-risk (IR) and high-risk (HR) groups, with FLIPI allowing a more even patient distribution among the risk groups. For patients receiving first-line chemotherapy within 6 months of diagnosis, a low FLIPI score was associated with a longer TTF (3-year TTF rates: 68.0, 33.7 and 31.0% for FLIPI-defined LR, IR and HR patients, respectively, p = 0.026). CONCLUSION Our data support the prognostic value of both IPI and FLIPI, with FLIPI demonstrating a more convenient patient distribution among risk classes. A low FLIPI score was also associated with a longer TTF. This might partially contribute to a more favourable prognosis.
Collapse
Affiliation(s)
- V Formica
- Department of Medicine, Royal Marsden Hospital, London and Sutton, UK
| | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Andrews N, Burris JE, Cech TR, Coller BS, Crowley WF, Gallin EK, Kelner KL, Kirch DG, Leshner AI, Morris CD, Nguyen FT, Oates J, Sung NS. Translational careers. Science 2009; 324:855. [PMID: 19443750 DOI: 10.1126/science.1172137] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
37
|
Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2009; 99:868-74. [PMID: 19238629 PMCID: PMC2538760 DOI: 10.1038/sj.bjc.6604622] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the humanised antiepidermal growth factor receptor monoclonal antibody matuzumab combined with epirubicin, cisplatin and capecitabine (ECX) in patients as first-line treatment for advanced oesophagogastric cancer that express epidermal growth factor receptor (EGFR). This was a phase I dose escalation study of matuzumab at 400 and 800 mg weekly and 1200 mg every 3 weeks combined with ECX (epirubicin 50 mg m−2, cisplatin 60 mg m−2 on day 1 and capecitabine 1000 mg m−2 daily). Patients were treated until disease progression, unacceptable toxicity or for a maximum of eight cycles. Twenty-one patients were treated with matuzumab at three different dose levels (DLs) combined with ECX. The main dose-limiting toxicity (DLT) was grade 3 lethargy at 1200 mg matuzumab every 3 weeks and thus 800 mg matuzumab weekly was the maximum-tolerated dose (MTD). Other common toxicities included rash, nausea, stomatitis and diarrhoea. Pharmacokinetic evaluation demonstrated that the coadministration of ECX did not alter the exposure of matuzumab. Pharmacodynamic studies on skin biopsies demonstrated inhibition of the EGFR pathway. Objective response rates of 65% (95% confidence interval (CI): 43–82), disease stabilisation of 25% (95% CI: 11–47) and a disease control rate (CR+PR+SD) of 90% were achieved overall. The MTD of matuzumab in combination with ECX was 800 mg weekly, and at this DL it was well-tolerated and showed encouraging antitumour activity. At the doses evaluated in serial skin biopsies, matuzumab decreased phosphorylation of EGFR and MAPK, and increased phosphorylation of STAT-3.
Collapse
Affiliation(s)
- S Rao
- Department of Medicine, Royal Marsden Hospital, Surrey, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, Nicolson M, Harper P, Seymour M, Hickish T. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 2009; 20:885-91. [PMID: 19164454 DOI: 10.1093/annonc/mdn716] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago-gastric junction (OGJ) versus gastric adenocarcinoma]. PATIENTS AND METHODS A total of 2110 patients were enrolled in four randomised controlled trials (RCTs) assessing fluoropyrimidine +/- platinum-based chemotherapy. This analysis used individual patient data and restricted to patients with adenocarcinoma who received one or more dose of chemotherapy. Gastric origin was the control in comparisons of tumour origin. RESULTS Of the 2110 patients randomised, 1775 (84%) patients had adenocarcinoma with oesophageal (n = 485), OGJ (n = 457) and gastric (n = 833) origins. The median OS was 9.5 months in oesophageal, 9.3 months in OGJ and 8.7 months in gastric cancer (P = 0.68). RR was 44.1% in oesophageal, 41.1% in OGJ and 35.6% in gastric cancers (P = 0.11 and 0.27, respectively, compared with gastric cancer on multivariate analysis). Toxicity composite end point occurred in 46%, 47% and 45% in oesophageal, OGJ and gastric cancers, respectively (P = 0.85 and 0.62 compared with gastric). CONCLUSIONS In our large multicentre RCT dataset, no significant differences were demonstrated on multivariate analyses in OS, RR and toxic effects among patients with advanced oesophageal, OGJ and gastric adenocarcinoma. Future RCTs should not exclude oesophageal adenocarcinoma.
Collapse
Affiliation(s)
- I Chau
- Department of Medicine, Royal Marsden Hospital, London
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
|
40
|
Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008; 19:1312-1319. [PMID: 18356139 DOI: 10.1093/annonc/mdn052] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT). PATIENTS AND METHODS Data on 195 patients who received ASCT between 1985 and June 2005 were reviewed. Median time from first treatment to ASCT was 2.6 years (0.4-27.3). Demography at ASCT was 61% stage IV, median age 31 years (18-69), median prior treatment (tx) regimens 3 (2-7), median Hasenclever index 3 (0-6); 150 patients had responding disease [54 complete remission (CR), 96 partial remission (PR)], and 45 patients had untested relapse/refractory disease. RESULTS Post-ASCT, 61% (119/195) patients attained CR with an overall response (CR + PR) of 85%. Twelve patients had nonrelapse mortality. Of 119 patients attaining CR, 27 relapsed: 3 after attaining CR for >5 years and 1 after attaining CR for >10 years. Median overall survival (OS)/progression-free survival (PFS) from ASCT was 9 years/2.9 years. Five-year OS/PFS was 55% of 44% and 10-year OS/PFS was 49.4% of 37% for whole group. Twenty (10%) patients developed second cancer (seven secondary acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS)). Probability of developing second cancer at 10 years was 14.7% (95% confidence interval 8.9% to 23.8%) and 24.8% at 19 years. CONCLUSION These data provide the longest follow-up reported for patients receiving ASCT for relapsed/refractory HL. In addition to previously described prognostic factors, our data show that Hasenclever index <3 influences outcome favorably and attaining CR at ASCT leads to a better outcome.
Collapse
Affiliation(s)
- B Sirohi
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| | - D Cunningham
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK.
| | - R Powles
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| | - F Murphy
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| | - T Arkenau
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| | - A Norman
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| | - J Oates
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| | - A Wotherspoon
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| | - A Horwich
- Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
| |
Collapse
|
41
|
Oates J, Jenkinson R, Stubington SR. The F-URS Screensaver - a cost-free aid to flexible ureterorenoscopy. Ann R Coll Surg Engl 2008; 89:636-7. [PMID: 18213742 DOI: 10.1308/rcsann.2007.89.6.636b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- J Oates
- Department of Urology, Mid-Cheshire Hospitals NHS Trust,Leighton Hospital, Crewe, Cheshire, UK.
| | | | | |
Collapse
|
42
|
Chau I, Starling N, Cunningham D, Oates J, Iveson T, Nicolson M, Hawkins R, Hickish T, Seymour M, Norman A. Does histology influence outcome in advanced oesophagogastric (OG) cancer? Individual patient data from 1,680 patients on three randomised controlled trials (RCT). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15001 Background: In advanced OG cancer, it is unclear whether squamous cell carcinoma (SCC) differs from adenocarcinoma (Ad) in its response to chemotherapy, as most phase III studies do not include both histology. The aim of this pooled analysis was to evaluate whether there is a differential chemotherapy effect on overall survival (OS), response rate (RR) and toxicity depending on tumour histology (SCC vs. Ad) using individual patient (pt) data. Methods: From 1994 to 2005, 3 RCTs were conducted assessing fluoropyrimidine ± platinum-based chemotherapy. This analysis was restricted to eligible pts with SCC or Ad histology who received =1 dose chemotherapy. Apart from OS and RR, a toxicity composite endpoint (TCE) was constructed - defined as occurrence of grades =3 diarrhoea, (febrile) neutropenia, infection, nausea & vomiting, grades =2 renal and neurotoxicity. Ad was used as the control group. Two-sided p values of <0.05 were considered significant. Results: Of the 1,836 pts randomised, 1,680 were included for this analysis of whom 1,536 (91%) had Ad and 144 (9%) had SCC. Locally advanced disease was present in 17% and 20% of Ad and SCC patients respectively. The median survival was 9.4 months with Ad and 7.7 months with SCC and one year survival rates were 38% and 29% respectively (log rank p= 0.115) and this remained non- significant on multivariate analysis (p=0.206). The RR was 40.4% (95% CI: 38–42.9%) in Ad and 33.3% in SCC (95% CI: 26.1–41.4%; p=0.109). TCE occurred in 45% and 44% of patients with Ad and SCC respectively (p=1.0). Time to TCE was not significantly different (log rank p=0.829). Conclusions: Although there was a trend towards worse survival with SCC, no significant differences in chemotherapy outcome were demonstrated, despite our large dataset. Molecular therapeutics targeting distinct biological pathways between the two histology subtypes may influence outcome more than cytotoxic combinations in the future. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Chau
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - N. Starling
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - D. Cunningham
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - J. Oates
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - T. Iveson
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - M. Nicolson
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - R. Hawkins
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - T. Hickish
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - M. Seymour
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| | - A. Norman
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Christie Hospital, Manchester, United Kingdom; Royal Bournemouth and Poole Hospital, Bournemouth and Poole, United Kingdom; Cookridge Hospital, Leeds, United Kingdom
| |
Collapse
|
43
|
Streit JBF, Oates J, David C, Sneddon L, Martin R, Obrien C. HN02 PATIENT RESPONSES TO THEIR MULTIDISCIPLINARY HEAD AND NECK CLINIC VISIT. ANZ J Surg 2007. [DOI: 10.1111/j.1445-2197.2007.04121_2.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
44
|
Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, Chong G. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer 2007; 96:1178-82. [PMID: 17406366 PMCID: PMC2360161 DOI: 10.1038/sj.bjc.6603699] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2007] [Revised: 02/21/2007] [Accepted: 02/22/2007] [Indexed: 11/09/2022] Open
Abstract
The World Health Organisation (WHO) classification (2000) is widely used to classify neuroendocrine carcinomas (NECs), yet its prognostic value needs to be confirmed. In this study, patients with metastatic NECs (n=119) were classified according to WHO guidelines into well differentiated and poorly differentiated (WDNECs and PDNECs). Histological differentiation based on WHO criteria had the highest impact on overall survival (OS) (PDNECs : WDNECs hazard ratio (HR)=4.02, P=0.02); however, PDNECs represented only a small percentage of patients (8%). In a WDNEC-restricted analysis, abnormal liver function tests (LFTs) and elevated urinary 5-hydroxyindoleacetic acid (u5HIAA) were independent prognostic factors for survival (HR=2.65, P=0.006 and HR=2.51, P=0.003, respectively) and were used to create a WDNEC-specific prognostic model (low risk=both normal, intermediate risk=one of them abnormal, high risk=both abnormal). Low-risk WDNECs had the most favourable prognosis (median OS, mOS 8.1 years), which was significantly better compared to both intermediate-risk and high-risk WDNECs (mOS 3.2 and 1.4 years, with P=0.01 and P<0.001, respectively). High-risk WDNECs displayed the shortest OS (1.3 years), which was similar to that of PDNECs (P=0.572). This analysis supports the prognostic value of WHO classification for metastatic NECs arising from the gastroenteropancreatic tract; however, risk stratification using readily available u5HIAA and LFTs may be necessary for the heterogeneous group of WDNECs.
Collapse
Affiliation(s)
- V Formica
- Department of Medicine, Royal Marsden Hospital, London and Sutton, Surrey, UK
| | - A Wotherspoon
- Department of Histopathology, Royal Marsden Hospital, London and Sutton, Surrey, UK
| | - D Cunningham
- Department of Medicine, Royal Marsden Hospital, London and Sutton, Surrey, UK
| | - A R Norman
- Department of Computing and Information, Royal Marsden Hospital, London and Sutton, Surrey, UK
| | - B Sirohi
- Department of Medicine, Royal Marsden Hospital, London and Sutton, Surrey, UK
| | - J Oates
- Department of Computing and Information, Royal Marsden Hospital, London and Sutton, Surrey, UK
| | - G Chong
- Department of Medicine, Royal Marsden Hospital, London and Sutton, Surrey, UK
| |
Collapse
|
45
|
Abstract
OBJECTIVE To identify the 'stapedotomy' learning curve of 2 UK otolaryngologists. STUDY DESIGN A retrospective review of the outcome of the first 100 stapedotomy operations by each surgeon. Included in the study was a postal survey of the incidence of stapes surgery by UK otolaryngologists. SETTING Two tertiary referral centres. PATIENTS All ears in which primary stapedotomy was performed for otosclerosis. Non-otosclerotic cases and malleus stapedotomy cases were excluded. INTERVENTION One surgeon used the technique of small fenestra stapedotomy with either a Teflon wire or titanium piston, but without vein graft interposition, whilst the second employed the technique of stapedotomy with vein graft interposition, and a Teflon piston. MAIN OUTCOME MEASURES The first 100 stapes operations performed by each surgeon were subdivided into consecutive groups of 10. Using a postoperative air-bone gap of 20 dB or better as a definition of 'success', the 'success rates' of each group were plotted on graphs - the learning curves. The end point of the learning curve was defined as the point 'where the curve reaches its plateau'. RESULTS The learning curves of both surgeons included 70-80 operations. Both surgeons had one 'dead ear' in their first 15 cases. The postal survey showed that some trainers only perform a small number of stapes surgeries, whereas some otolaryngologists who regularly perform stapedotomies were not trainers. CONCLUSIONS This is a mismatch of trainers and trainees in stapes surgery. If the current trend of decline in stapes surgery continues, it will take many years for some otolaryngologists to complete their learning curves.
Collapse
Affiliation(s)
- M W Yung
- Department of Otolaryngology, The Ipswich Hospital NHS Trust, Ipswich, UK
| | | |
Collapse
|
46
|
Sirohi B, Cunningham D, Norman AR, Oates J, Wotherspoon A, Chong G, Arkenau T, Horwich A. Long-term outcome of high-dose chemotherapy and autologous stem cell transplantation in relapsed/refractory Hodgkin’s disease: A cohort of 199 pts from Royal Marsden Hospital. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7622] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7622 Background: The purpose was to assess prognostic factors and outcome of pts with relapsed/refractory Hodgkin disease (HD) who have received high-dose chemotherapy and autologous stem cell transplant (ASCT). Methods: The retrospective study was approved by Research Ethics Committee. Primary end-point was overall (OS) and progression free survival (PFS). OS was defined as death from any cause measured from date of transplant and PFS defined as disease progression or death from any cause. Data on 199 pts who received ASCT between 1985–6/05 was reviewed. Results: Median time from 1st treatment(tx) to ASCT was 2.5 y (0.5–27.3). Demography at ASCT:61% Stage IV, median age 31y(18–69); median prior tx regimens 3 (1–7); median Hasenclever index 3 (0–6); 150 pts had responding disease (53 CR, 97 PR), 49 pts had stable/untested relapse/refractory disease. 62% pts received MBE as conditioning tx and bone marrow was source of stem cells in 57%. Post-ASCT, 61% (122/199) pts attained CR with an overall response (CR+PR) of 85%. 12 pts had non-relapse mortality;10 died before 1990 of interstitial pneumonitis (with higher dose BCNU). Of 122 pts attaining CR, 27 relapsed;3 after attaining CR for >5y and 1 after attaining CR for>10-y. 5-y risk of relapse in patients attaining CR was 21%. Median OS/PFS from ASCT was 9y/2.6y. 105 pts are alive at median follow-up of 10.3y. 5-y OS/PFS was 52/45% and 10-y OS/PFS was 49.5/41% for whole group. 10-y OS/PFS for pts in CR vs PR vs rest at ASCT was 72/66% vs 55/44% vs 11/5%. 20(10%) pts developed 2nd cancer (7 secondary AML/MDS). Probability of developing 2nd cancer at 10y is 6.9% (95%CI 3.6–13%) and 19.8% (95%CI 12–32%) at 20-y. Conclusions: These data provide the longest followup reported for patients receiving ASCT for relapsed/refractory HD. In addition to previously described prognostic factors, our data shows that Hasenclever index <3 influences outcome favorably and attaining CR at ASCT leads to a significantly better outcome. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Sirohi
- Royal Marsden Hospital, Sutton, United Kingdom
| | | | | | - J. Oates
- Royal Marsden Hospital, Sutton, United Kingdom
| | | | - G. Chong
- Royal Marsden Hospital, Sutton, United Kingdom
| | - T. Arkenau
- Royal Marsden Hospital, Sutton, United Kingdom
| | - A. Horwich
- Royal Marsden Hospital, Sutton, United Kingdom
| |
Collapse
|
47
|
Formica V, Norman AR, Cunningham D, Wotherspoon A, Sirohi B, Oates J, Chong G. The prognostic role of the WHO classification, urinary 5-hydroxyindoleacetic acid (u5HIAA) and liver function tests (LFTs) in metastatic neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4092 Background: The aim of this study was to assess the prognostic value of the revised neuroendocrine tumour (NET) WHO classification (2000) and to identify additional prognostic factors. Methods: 119 pts with metastatic NET arising from the GEP tract treated at the RMH were eligible for this retrospective study. All were classified according to WHO guidelines into well-differentiated and poorly-differentiated neuroendocrine carcinomas (WDNEC and PDNEC). Demographic, clinical and biochemical data at diagnosis were recorded as potential prognostic factors. The hazard ratios (HRs) between subgroups of patients were estimated by Cox regression analysis; survival curves were generated by Kaplan-Meier method. Approval for the study was obtained from the local ethics committee. Results: 8% of pts had PDNECs, 92% had WDNECs. Histological differentiation had the most impact on overall survival (OS) (HR = 4.02, 95%CI 1.26–12.82, p = 0.02, using WDNECs as the reference). In a WDNEC-restricted multivariate analysis, significantly abnormal LFTs and elevated u5HIAA were independent prognostic factors for survival (HR = 2.65, 95% CI 1.33–5.30, p = 0.006 and HR = 2.51, 95% CI 1.35–4.63, p = 0.003, respectively). Radiological evidence of liver metastases was not predictive of survival. These variables were used to create a WDNEC-specific prognostic model (low-risk = both normal, intermediate-risk = one abnormal, high-risk = both abnormal) (see table ). Statistically distinct median OS (mOS) were identified for each of the 3 risk groups. High-risk WDNECs had similar poor survival to PDNECs. Conclusion: This analysis supports the prognostic value of the WHO classification for metastatic NETs arising from the GEP tract. Risk stratification using readily available u5HIAA and LFTs may give additional prognostic information for WDNECs, although these observations need to be confirmed in an independent dataset. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Formica
- Royal Marsden Hospital, Sutton Surrey, United Kingdom
| | - A. R. Norman
- Royal Marsden Hospital, Sutton Surrey, United Kingdom
| | - D. Cunningham
- Royal Marsden Hospital, Sutton Surrey, United Kingdom
| | | | - B. Sirohi
- Royal Marsden Hospital, Sutton Surrey, United Kingdom
| | - J. Oates
- Royal Marsden Hospital, Sutton Surrey, United Kingdom
| | - G. Chong
- Royal Marsden Hospital, Sutton Surrey, United Kingdom
| |
Collapse
|
48
|
Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.lba4017] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA4017 Background: The aim was to establish the potential use of the third generation platinum compound, oxaliplatin (O) & the oral fluoropyrimidine capecitabine (X) in untreated patients (pts) with advanced OG cancer. Methods: After stratification for PS and extent of disease, pts with histologically confirmed adenocarcinoma, squamous or undifferentiated carcinoma of the oesophagus, oesophago-gastric junction or stomach were randomised, in a 2 x 2 design, to 1 of 4 regimens; epirubicin, cisplatin, fluorouracil (ECF), EOF, ECX or EOX. Doses E 50 mg/m2, C 60 mg/m2 & O 130 mg/m2 IV 3 weekly; F 200 mg/m2 IV daily & X 625 mg/m2 twice daily PO continuously; for 8 cycles. The primary endpoint was overall survival. With 1000 pts (250 per arm) the study had 80% power to demonstrate non-inferiority of X over F and also O over C if the upper limit of the HR 95% CI excluded 1.23 (α = 0.05) in the per protocol population. Analysis was performed using the logrank test and Cox regression analysis. Results: 1002 pts were randomised from 61 centres. Demographics were balanced, 89% were PS 0–1, 77% metastatic, median age 63 (range 22–83), 81% were male and 40% gastric primaries. Histology: adenocarcinoma in 88% and 52% poorly differentiated. 11 pts were ineligible and 27 pts were withdrawn before treatment commenced. Median follow up was 17.1 months and 850 events have occurred. There were no significant differences in response rates comparing ECF to, EOF, ECX and EOX (41%, 42%, 46%, and 48% respectively); grade 3–4 non haematological toxicity 36%, 42%, 33% and 45%; and grade 3–4 neutropaenia 42%, 30% (p = 0.008), 51% (p = 0.043) and 28% (p = 0.001) respectively. Conclusions: Capecitabine may replace 5FU and Oxaliplatin may replace Cisplatin in triplet regimens used for the treatment of advanced OG cancer. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- D. Cunningham
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - S. Rao
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - N. Starling
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - T. Iveson
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - M. Nicolson
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - F. Coxon
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - G. Middleton
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - F. Daniel
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - J. Oates
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| | - A. R. Norman
- Royal Marsden NHS Trust, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Newcastle General Hospital, Newcastle upon Tyne, United Kingdom; St Lukes Cancer Centre, Guildford, United Kingdom; Derriford Hospital, Plymouth, United Kingdom
| |
Collapse
|
49
|
Smith GI, Yeo D, Clark J, Choy ET, Gao K, Oates J, O'Brien CJ. Measures of health-related quality of life and functional status in survivors of oral cavity cancer who have had defects reconstructed with radial forearm free flaps. Br J Oral Maxillofac Surg 2006; 44:187-92. [PMID: 16095776 DOI: 10.1016/j.bjoms.2005.06.022] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2004] [Accepted: 06/24/2005] [Indexed: 11/17/2022]
Abstract
The aim of this study was to evaluate (by postal questionnaire) quality of life and function in patients who have had resections of oral cancer and reconstruction by radial forearm flaps. Between October 1987 and December 2002, 258 patients had reconstructions by radial forearm flaps after resection of tumours in the oral cavity. Of these, 139 surviving patients were identified from the database and were sent questionnaires comprising five sections: Functional Assessment of Cancer Therapy-General (FACT-G) and -Head and Neck (FACT-HN); University of Washington Quality of Life Scale (UWQoL); Performance Status Scale for Head and Neck Cancer (PSS-HN); and the final section addressed dental rehabilitation and morbidity at the donor site. Sixty-three questionnaires (45%) were returned. In 17 (27%), parts of the questionnaire were incomplete. The median UWQoL score was 623/900, FACT-G was 92/108, FACT-HN was 31/48, and PSS-HN showed that eating in public, understandability of speech and normality of diet were 75/100, 75/100 and 50/100, respectively. The effect of stage and site on quality of life and function did not reach statistical significance. The effect of radiotherapy on speech (p=0.036) and diet (p=0.007) was significant. Patients who worried about their cancer returning had a lower UWQoL score (p=0.016). Ninety percent regarded their arm as disfigured, but 81% felt comfortable wearing short-sleeved shirts. Sensation and function of the hand were reported as normal in 87 and 92%, respectively. We conclude that patients who have had oral cancer have a persistent reduction in quality of life and function long after completion of treatment. The effects can be assessed by postal questionnaire, but the low rate of return (45%) and difficulties with completion reduce the quality of the data. Quality of life and function are essential components of improvements in outcome.
Collapse
Affiliation(s)
- G I Smith
- Sydney Head and Neck Cancer Institute, Royal Prince Alfred Hospital, Sydney 2042, Australia.
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
OBJECTIVE To identify the stapedotomy learning curve of two U.K. otolaryngologists. STUDY DESIGN A retrospective review of the outcome of first 100 stapedotomy operations by each surgeon. Included in the study was a postal survey of the incidence of stapes surgery by U.K. otolaryngologists. SETTING Two tertiary referral centers. PATIENTS All ears in which primary stapedotomy was performed for otosclerosis. Nonotosclerotic cases and malleus stapedotomy cases were excluded. INTERVENTION One surgeon used the technique of small fenestra stapedotomy with either a Teflon-wire or titanium piston but without vein graft interposition, whereas the second used the technique of stapedotomy with vein graft interposition and a Teflon piston. MAIN OUTCOME MEASURES A moving average with a window of 15 dB was used to plot learning curves for the postoperative air-bone gaps. Using a postoperative air-bone gap of 20 dB or better as a definition of 'success,' the success rates with the increase in surgical experience of both surgeons were plotted on graphs, the learning curves. The end point of the learning curve was defined as the point where the curve reached its peak, and the results were sustainable. RESULTS There was no clear-cut end point in both learning curves, although it appears that there is a landmark point at 60 to 80 cases for both surgeons. Both surgeons also had one "dead ear" in their first 15 cases. The postal survey showed that some trainers only performed small numbers of stapes surgery, whereas some otolaryngologists who performed stapedotomies regularly were not trainers. CONCLUSIONS The study supports a learning curve in stapes surgery. To maximize the training opportunity of trainee surgeons, it may be advisable for learning centers to form network to provide target training for the trainee who has demonstrated the necessary dexterity and temperament of an otologist.
Collapse
Affiliation(s)
- M W Yung
- Department of Otolaryngology, The Ipswich Hospital NHS Trust, Ipswich, Suffolk, UK.
| | | | | |
Collapse
|